Nicheloom

Market intelligence for builders — see what's gaining traction before it's crowded.

Ditto Bio – Evolutionary therapies for autoimmune disease

We discover new drugs by harnessing parasite biology

Details

External ID
97563
Source
YC
Company
Ditto Biosciences
Product
Ditto Bio – Evolutionary therapies for autoimmune disease
Website domain
dittobio.com
Launched
Feb. 6, 2026
Cohort
Winter 2026
Upvotes
161
Upvotes percentile
0.9534883720930233
Tags
—
Fetched at
Sept. 30, 2026, 5 p.m.
Updated at
Sept. 30, 2026, 5 p.m.

Enrichment

Theme
computational biology and personalized therapeutics
Vertical
Healthcare
Function
—
Audience
B2B
AI stance
Not AI
Project type
Commercial product
Normalized one-liner
drug discovery for autoimmune disease
Manually corrected
False

Could you build this?

No Ditto Bio is a biotechnology company discovering therapeutics from parasite biology, which fundamentally requires physical wet-lab experimentation, biochemistry, and clinical drug validation.

What it would actually take: Developing evolutionary therapies requires biological wet labs equipped for culturing parasitic organisms, isolating bioactive secretomes, and running high-throughput mass spectrometry and proteomics assays. Computationally, it needs structural biology models and molecular dynamics pipelines to identify potential autoimmune modulators, followed by in vitro and in vivo animal disease model testing. Bringing these discoveries forward demands specialized molecular biology, immunology, and pharmacology teams capable of navigating preclinical IND-enabling studies.

Competitors

Other products that read as similar to this one — 51 launches clear the similarity bar, closest 8 shown.

Attention rank: #6 of 52 (itself plus its competitors, highest first — normalized so YC and Product Hunt are compared fairly).

Launched 91 days after the earliest competitor.

Other launches for this product